The Medical Letter on Drugs and Therapeutics
Drugs for Atrial Fibrillation
September 9, 2019 (Issue: 1580)Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
- CT January et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation 2019; 140:e125.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019; March 12 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- SJ Connolly et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.
- MR Patel et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883.
- CB Granger et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.
- RP Giugliano et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093.
- Dabigatran etexilate (Pradaxa) – a new oral anticoagulant. Med Lett Drugs Ther 2010; 52:89.
- MR Southworth et al. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272.
- FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: Available at: www.fda.gov. Accessed August 29, 2019.
- Idarucizumab (Praxbind) – an antidote for dabigatran. Med Lett Drugs Ther 2015; 57:157.
- Rivaroxaban (Xarelto) – a new oral anticoagulant. Med Lett Drugs Ther 2011; 53:65.
- Andexxa – an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther 2018; 60:99.
- C Dias et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016; 43:229.
- Apixaban (Eliquis) — a new oral anticoagulant for atrial fibrillation. Med Lett Drugs Ther 2013; 55:9.
- X Wang et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56:628.
- Edoxaban (Savaysa) – the fourth new oral anticoagulant. Med Lett Drugs Ther 2015; 57:43.
- M Crowther et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 2014; 124:4269.
- SJ Connolly et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326.
- DR Holmes et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015; 65:2614.
- SM Al-Khatib et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014; 160:760.
- IC Van Gelder et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362:1363.
- Safety of dronedarone (Multaq). Med Lett Drugs Ther 2011; 53:103.
- RL Woosley et al. QT drugs list. Available at: www.crediblemeds.org. Accessed August 29, 2019.
- JM Abraham et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015; 8:772.
- GA Upadhyay and FJ Alenghat. Catheter ablation for atrial fibrillation in 2019. JAMA 2019; 322:686.
- HS Abed et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310:2050.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.